Danaher is tapping the M&A well yet again. But we might have had enough
Danaher ‘s days in the portfolio may be numbered. We’re again left disappointed after Danaher’s latest acquisition plan failed to inspire Wall Street. Shares of the life sciences giant lost more than 3.5% following Tuesday’s announcement that the company agreed to buy medtech Masimo for $180 per share in cash, or more than $9.6 billion. Masimo…